SPEECH-PROCESSING-SOLUT
2.11.2016 15:02:22 CET | Business Wire | Press release
Speech Processing Solutions , the world’s number one in professional dictation solutions , is proud to announce that thanks to its wide-spread success, Philips SpeechLive is now also being made available in Italy, Ireland, Finland, Spain, Sweden and South Africa.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161102005054/en/
Your personal transcription service at your finger tips
The dictation workflow solution Philips SpeechLive helps save time by turning people’s voice into written text. Alongside a classic transcriptionist service , it now also offers an on-demand speech recognition service in over twenty languages, allowing users to get more work done, in less time.
Getting work done on the go
The solution is perfectly suited for people who are on the go. Recordings can be sent using the Philips dictation app using a smartphone or a Philips voice recorder , such as the Philips Pocket Memo 8000 series. “We developed Philips SpeechLive to help improve the lives of busy professionals. You can stop loosing time by focusing on your core tasks, and have documents, notes and meeting minutes simply typed up for you” explains Dr Thomas Brauner, CEO of Speech Processing Solutions. He continues: “We received so much positive feedback since we implemented our new speech recognition service feature that we decided to expand our reach to new countries.”
Easy to implement and even easier to use
The solution is extremely easy to adopt. It requires no installation and can be accessed using a normal web browser. Tony Oakley, Principal at the Australian law firm Hicks Oakley Chessell Williams in Melbourne explains: “Coming from an analog solution, we were very happy at how easy and intuitive our dictation workflow solution is.” His officer manager, Nicole Honan adds: “For me, it is very convenient that I can work the same from any location, I don’t have to think about taking something with me.” Regardless of the industry, Philips SpeechLive can help speed up users’ daily workflow by saving them lost typing time . “Philips SpeechLive is as simple as speak, send, done” concludes Dr Brauner.
Philips is now offering a 30-day free trial of their software, including 10 free speech recognition service minutes. Visit www.speechlive.com for more information.
About Speech Processing Solutions
Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir , the Philips Pocket Memo voice recorder , the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the newest innovation, Philips SpeechLive , dictations and recordings will become faster and easier than ever before with cloud-based workflow services. Speech Processing Solution's perfectly tailored offers and products help professionals save time and resources and maximize efficiency.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Instagram: https://www.instagram.com/philips_dictation/
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102005054/en/
Contact:
Speech Processing Solutions
Lea Pachta
lea.pachta@speech.com
Tel:
+43 1605 291 744
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom